Kornimate/medical-research-clean huggingface dataset:
development and validation of an automated self-administered visual acuity system

Conditions: Visual Impairment

Summary: visual acuity tests, commonly conducted in clinics and used for health screenings, are becoming more in demand due to an aging population. current online self-eye check apps are limited as they don\&#39;t accurately reflect true distance vision assessed in clinical settings. these tests, performed by trained personnel, are time-consuming and can cause delays in clinics. this project aims to develop an automated visual acuity (va) station using ai technologies like speech-to-text and computer vision, hypothesizing that it can match the accuracy of manual assessments by clinic staff, thus potentially reducing waiting times and improving efficiency.

visual acuity is done as a routine eye check for the majority of eye patients in the clinic. it is also done as a screening test for pre-employment health checks and health screening. patients can be checked for refractive errors, on a community level or screened for eye diseases, for those with chronic medical conditions. with the increasing burden of aging population and eye conditions, the number of patients in eye clinics will increase. there are a few existing online applications that allow self-eye checks, however there are limitations. they are usually done at an intermediate distance, i.e. distance from phone to eye and does not accurately represent true distance vision. distance vision is typically set at 4- 6m in a clinical setting. a visual acuity test is administered by specially trained healthcare personnel, such as optometrists and patient service assistants, which is often time-consuming and labour intensive, where one-on-one attention is required. in addition, vision is subjective and re-testing may be required at times to ensure accurate vision assessment. as the visual acuity test is the first clinical station patient goes to after registration, this leads to a bottleneck in workflow causes delays in the subsequent services and eventually increases patient waiting times in the clinics. this project aims to develop and validate an automated visual acuity (va) station through speech-to-text and computer vision technology in comparison to existing manual va assessments. we hypothesize that we are able to use artificial intelligence to understand patient\&#39;s speech and posture to automate the visual acuity test. we also hypothesize that the automated visual acuity test is comparable to having va checked manually by a clinic staff.

Eligibility criteria:
inclusion criteria: 1. patients age \&gt;21 and able to give consent 2. patients who have at least counting finger vision 3. patients who is able to speak in an audible and clear voice 4. patients who is able to use a digital device independently (e.g. handphone) exclusion criteria: 1. patients on wheelchair/ walking aids 2. patients with hearing difficulties 3. patients with speech difficulties 4. patients who have cognitive impairment 5. patients who are hemiplegic/ motor dysfunction 6. patients who have vision worse than counting fingers 7. patients who are pregnant

Keywords: visual acuity
safety and efficacy study to compare uniplas with cryosupernatant plasma in thrombotic thrombocytopenic purpura (ttp)

Conditions: Thrombotic Thrombocytopenic Purpura (TTP)

Summary: prior to the use of plasma products, thrombotic thrombocytopenic purpura (ttp) was usually a fatal condition. during plasma exchange therapy, patients need transfusion plasma that is blood group specific. transfusing a patient with an incorrect blood group may have fatal consequences. uniplas is a universally applicable human plasma, which can be administered irrespective of the patient's blood group. this study will test the safety and efficacy of uniplas in comparison to cryosupernatant plasma in treatment of patients with ttp.


Eligibility criteria:
inclusion criteria: * 18 years of age and above. * definite diagnosis of acute thrombotic thrombocytopenic purpura (ttp). * thrombocytopenia. * diagnostic signs of microangiopathic hemolytic anemia. exclusion criteria: * congenital thrombotic microangiopathies. * alternative secondary cause for microangiopathy. * co-morbid illness limiting life expectancy to less than 3 months independent of ttp. * patients known to be hiv positive. * patients known to have lupus. * refusal to accept blood products.

Keywords: bleeding disorder universal plasma plasma plasma exchange
equine-assisted occupational therapy for children with autism spectrum disorder

Conditions: Autism Spectrum Disorder

Summary: children with autism spectrum disorder have difficulty engaging in activities. this study examined the effects of equine-assisted occupational therapy for 7 children with asd ages 4 to 8 years. a multiple baseline design was used. for each child, there were 9 to 11 baseline assessments, 9 to 12 intervention sessions, and 4 follow-up sessions.

children with autism spectrum disorder (asd) have difficulty engaging in activities. based on the literature, the unique features of horses may be beneficial to children with asd. there is limited research supporting the use of horses in occupational therapy interventions. this study examined the effects of equine-assisted occupational therapy for 7 children with asd ages 4 to 8 years. a multiple baseline design was used. for each child, there were 9 to 11 baseline assessments (gross and fine motor play activities), 9 to 12 intervention sessions, and 4 follow-up sessions (gross and fine motor play activities). intervention sessions were 40 to 60 minutes long and consisted of time spent on the horse and in horse related activities. children were videorecorded in all conditions. trained coders scored randomly selected segments of the video recording. inter-rater reliability was good.

Eligibility criteria:
inclusion criteria: * diagnosis of autism spectrum disorder by a multidisciplinary team, * between ages 3 and 8, * understand basic english, * willing to ride a horse, no horse riding in the past 3 months. exclusion criteria: * severe of repeated aggressive behaviour, * comorbidities such as deafness that would interfere with intervention.
improving albuminuria screening compliance using a smartphone urinalysis kit

Conditions: Albuminuria; Chronic Kidney Diseases; Cardiovascular Diseases; Hypertension

Summary: this study will test the effectiveness of mailed, smartphone urinalysis kits to improve albuminuria screening compliance and detection of albuminuria.

this proposal will examine the effect of mailed, smartphone urinalysis kits to improve albuminuria screening compliance and detection of albuminuria. the investigators will randomize 1,000 non-diabetic mygeisinger portal users with hypertension and last clinic blood pressure \>= 130/80 mmhg who have not received albuminuria screening to either: 1) control - usual care or 2) intervention - mailed urinalysis smartphone kit. all patients will first receive a reminder letter to have albuminuria screening completed at their clinic in coordination with the geisinger care gap team. patients randomized to the intervention arm who do not complete this initial screening test will then be offered a mailed, smartphone urinalysis testing kit. patients with 1+ or greater detected urine protein will be recommended to have urine albumin/creatinine ratio (acr) testing to confirm albuminuria. patients with acr \>= 30 mg/g will be referred to pharmacists for optimal treatment of albuminuria (ace or arb, statin, bp goal \<130/90 mmhg).

Eligibility criteria:
inclusion criteria: * 18 and older * hypertension * last outpatient bp ≥ 130/80 mmhg * active mygeisinger users with a listed mobile phone number * has a geisinger pcp and followed by the care gaps team * no prior urine albuminuria test (urine dipstick, albumin/creatinine ratio, protein/creatinine ratio) exclusion criteria: * history of diabetes * receiving dialysis * history of kidney transplant * egfr \< 15 ml/min/1.73m2 * principal investigator or pcp discretion (i.e. concerns about safety, compliance)
effect of a vibration system on pain reduction during injection of local dental anaesthesia in children

Conditions: Local Anaesthetic; Dental Anxiety

Summary: the study assesses the effect of a new vibration system on pain reduction during the injection of local anesthesia. children undergoing dental treatment are allocated to two groups; one receiving the buzz, a vibration system and another group receiving nothing. pain during injection of local anesthetic is assessed using a validated tool in addition to assessment of child cooperation during treatment.

eligibility of children for inclusion into the study will be assessed followed by random sequence generation and randomization into one of the two study group and allocation concealment. topical anaesthesia will be administered to the two groups followed by implementation of the vibration system in the test group. . behavior and pain will assessed at the time of injection.

Eligibility criteria:
inclusion criteria: 1. children 5-12 years of age. 2. positive or definitely positive behavior on frankl scale.6 3. children receiving treatment on the dental chair. 4. free from allergies to topical anesthetic used in the study. 5. parental consent for child participation in the study. exclusion criteria: 1. those in need of treatment under general anesthesia will be excluded from the study. 2. children with allergies from topical anesthesia
first-line bevacizumab and chemotherapy in metastatic cancer of the colon or rectum - international study

Conditions: Colonic Neoplasms; Rectal Neoplasms

Summary: first-line bevacizumab and chemotherapy in metastatic cancer of the colon or rectum


Eligibility criteria:
inclusion criteria: * patients with metastatic cancer of colon or rectum

Keywords: colon and rectum cancer
evaluation of copeptin in patients with cirrhosis and ascites

Conditions: Cirrhotic Patients With Ascites

Summary: copeptin is a glycopeptide released by the post-pituitary gland. in case of decrease in blood volume or blood pressure, it is secreted in the serum in an equimolar quantity to arginine vasopressin (avp) . unlike avp, copeptin is readily assayable in serum and its prognostic value has been recently observed during cirrhosis. however, the pathophysiological relationships between serum copeptin concentrations and indirect markers of inflammation are unknown. the main objective of this multicenter pilot study is to study the relationship between serum copeptin and markers of inflammatory stress in cirrhotic patients with ascites. it is indeed in this population with high-risk of complications that most need biomarkers of events (like death) are needed. the main secondary objective is to evaluate the prognostic interest at 6 months of the variation of copeptin between day 0- day15.

the investigators wish to include prospectively 100 cirrhotic patients with ascites requiring prolonged hospitalization in the hepato-gastroenterology departments of the besançon, nancy and reims hospitals. the inclusion and follow-up periods will be six months each. at the inclusion of the patients we will evaluate the correlations between the plasma concentration of copeptin and 1 / the severity of cirrhosis (child-pugh and meld scores) and serum sodium; 2 / systemic inflammation markers (crp, leukocytes, il-6 and lipopolysaccharides), 3 / calprotectin concentration in ascites. "

Eligibility criteria:
inclusion criteria: * man or woman * age between 18 and 80 years * acute decompensation of cirrhosis with occurrence of ascites * hospitalisationfor a complication of cirrhosis (first occurrence of ascites or recurrent ascites requiring hospitalization, gastrointestinal bleeding, hepatic encephalopathy, etc..) * patients participating to ca-drisla study * information and consent form signed exclusion criteria: * pregnant or breastfeeding woman * age minor to 18 years * age major to 80 years * adult under protection law * outpatients hospitalized for paracentesis * ascites not related to portal hypertension (pancreatic ascites, peritoneal carcinosis...) patients with hepatocellular carcinoma could be included

Keywords: cirrhotic ascite copeptin
endoscopic fhl transfer for acute achilles tendon rupture

Conditions: Achilles Tendon Rupture; Achilles Tendon Injury; Achilles Tendon Surgery; Flexor Hallucis Longus

Summary: this observational study aims to evaluate the outcome of endoscopic flexor hallucis longus transfer (fhlt) in patients with acute achilles tendon rupture (aatr).

this evaluation will be performed by examining the following parameters: 1. patient satisfaction quantified with the achilles tendon total rupture score (atrs). this is the primary outcome. 2. complication rate 3. ankle and calf circumference compared to the contralateral healthy limb. 4. passive and active range of ankle motion compared to the contralateral healthy limb. 5. hallux flexion force compared to the contralateral healthy limb.

Eligibility criteria:
inclusion criteria: * signed consent form * acute achilles tendon rupture (\<4 weeks) * underwent operative treatment with endoscopic flexor hallucis longus transfer * more than 24 months postoperative follow-up * patients operated after 2015 exclusion criteria: * inability or unwillingness to cooperate * medically unfit for examination * age less than 18 or more than 75 years * non-operative management or any other surgical management * neglected achilles tendon rupture (\>4 weeks) * bilateral achilles tendon rupture * patients operated before 1.1.2015 or after 1.1.2023 * comorbidities interfering with the secondary outcomes (e.g. venous insufficiency resulting in lower limb excessive edema interferes with ankle and calf circumference, rheumatoid arthritis and/or previous foot and ankle surgery interferes with active and passive range of motion of the ankle, etc)

Keywords: achilles tendon, rupture, endoscopic, flexor hallucis longus transfer
effect of liraglutide on blood glucose control in subjects with type 2 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted in europe. the trial is designed to show the effect of treatment with liraglutide or placebo on blood glucose control after 14 weeks in subjects with type 2 diabetes. liraglutide or placebo is administered by injection once daily in the evening. the trial is a multi-national trial with treatment concealed to participating subjects, investigators and the sponsor. treatment allocation is random with equal chance of being assigned to each group.


Eligibility criteria:
inclusion criteria: * subjects diagnosed with type 2 diabetes mellitus and treated with either diet or single oral drug therapy * diet treated subjects: 7.5% \< hba1c \< 10% * single oral drug therapy subjects: 7.0% \< hba1c \< 9.5% * body mass index (bmi): max 40 kg/m\^2 exclusion criteria: * subjects treated with thiazolidinediones or insulin * subjects with any serious medical conditions
effects of an exercise program for children with asthma

Conditions: Asthma

Summary: exercise program in the pulmonary function and cardiorespiratory fitness in children with asthma and respiratory symptoms

this study aims to analyze the effects of an exercise program in the pulmonary function, cardiorespiratory fitness, diet quality index, physical activity, body composition, muscle function, agility, and psychological health in a group of children with asthma and respiratory symptoms

Eligibility criteria:
inclusion criteria: * diagnosed with asthma following the gema 2009 criteria (spanish guide for asthma management) at least 6 months prior to the study. * complete successfully both cardiorespiratory and functional tests. exclusion criteria: * diagnosed with other chronic respiratory disease or condition * diagnosed with any chronic disease including cardiovascular diseases. * reduced mobility * uncooperative * poor adherence to medication

Keywords: asthma respiratory symptoms exercise program functional capacity body composition
enhancing a high school based smoking cessation program

Conditions: Nicotine Dependence

Summary: the purpose of this study is to examine the the efficacy of adjunctive nicotine replacement therapy when used in combination with the contingency management (cm) + cognitive behavioral therapy intervention. subjects will be randomly assigned to receive either a nicotine transdermal patch or a placebo patch as well as being randomly assigned to receive either cm or no cm; all subjects will receive cognitive behavioral therapy. we hypothesize that that subjects receiving both active nicotine patch and cm will have higher rates of abstinence from tobacco than subjects in the other groups.


Eligibility criteria:
inclusion criteria: * high school aged * desire to quit smoking * smoking \>5 cigarettes per day * able to read and write in english exclusion criteria: * current dependence on other substances * medical conditions that would contraindicate the use of a nicotine patch

Keywords: smoking adolescents contingency management nicotine replacement therapy
cryoablation for small tumors as local treatment - six trial

Conditions: Breast Cancer; Breast Neoplasm

Summary: to demonstrate the non-inferiority of cryoablation compared to breast surgery for the local treatment of early-stage breast cancer and to conduct a cost-minimization analysis comparing direct costs between treatments.

this study compares cryoablation with breast surgery for the treatment of early-stage breast cancer (t1n0m0), evaluating locoregional recurrence, cost-minimization, and disease-free survival. the primary objective is to demonstrate the non-inferiority of cryoablation compared to breast surgery for local treatment of early-stage breast cancer over five years, as well as to perform a cost-minimization analysis to compare the direct costs of both treatments over one year. the secondary objectives include assessing locoregional recurrence at one year, evaluating disease-free survival and overall survival over five years, analyzing circulating tumor cells (ctcs) as prognostic factors and for monitoring cryoablation at baseline (study inclusion), six months, and twelve months, measuring patient satisfaction one year after randomization using the breast-q questionnaire, and assessing quality of life using the eq-5d questionnaire. cryoablation is a nonsurgical, minimally invasive technique that destroys tumor tissue through cyclic freezing and thawing using cryoprobes. this process induces cellular death without requiring hospitalization, allowing for faster recovery. additionally, the study incorporates a de-escalated and personalized approach to breast cancer treatment by omitting sentinel lymph node biopsy, integrating ultrahypofractionated radiotherapy, and utilizing liquid biopsy.

Eligibility criteria:
inclusion criteria: * unifocal primary invasive breast carcinoma * tumor size ≤ 2.0 cm (t1) * complete pathological report (including results for er, pr, her2, ki-67, and fish report for the erbb2 gene, if necessary) * lesion visible on ultrasound * surgical treatment would be the first option, regardless of immunohistochemistry results exclusion criteria: * multifocal or multicentric invasive breast carcinoma * ductal carcinoma in situ * breast cancer with skin involvement * clinically positive axilla (n1, n2 or n3) * distance from lesion and skin less than 5 mm * prior neoadjuvant systemic therapy for breast cancer * distant metastasis

Keywords: breast cancer minimally invasive surgical procedures cryoablation locoregional recurrence cost-minimization analysis
a randomized control trial of a responsive parenting intervention to support healthy brain development and self-regulation in toddlers born preterm

Conditions: Premature Birth

Summary: the purpose of this study is to determine whether participation in the play and learning strategies (pals) parenting intervention results in increased caregiver responsiveness behaviors and to test if participation in pals results in increases in toddler skills and/or toddler neurological development.


Eligibility criteria:
inclusion criteria: - maternal age over 18-years when child was born exclusion criteria: * presence of known/suspected congenital anomalies including chromosomal or complex congenital heart disease * congenital infection including torch (toxoplasmosis, rubella, cytomegalovirus, herpes simplex and others),untreated maternal hiv, or maternal syphilis * bilateral grade 3/4 intraventricular hemorrhage,intraparenchymal hemorrhage, hydrocephalus * cerebral palsy with gross motor function classification of iii or higher * blindness- * deafness * current maternal drug use or maternal drug use during pregnancy * families who reside outside the catchment area (\>1 hour drive from the texas medical center) * child with contraindication for mri. if the mother of the child is pregnant, thinks she might be pregnant, or has a contraindication for mri, another relative of the child will be asked to assist with the mris
a real-world study for patients with multiple pulmonary ground-glass nodules

Conditions: Multiple Pulmonary Nodules

Summary: the purpose of this study is to actively monitor patients with multiple pulmonary ground-glass nodules (ggns), in order to provide evidence for multiple ggns treatment.

multiple pulmonary ggns are very commonly identified particularly as increasing numbers of ct scans are performed as part of routine lung cancer screening. at the same time, the ideal solution for these cases continues to be debated. this aim of this study is to learn more about the effects of multiple factors on outcome of multiple pulmonary ggns, such as patients' clinical characteristics, ct features and different pathological types. furthermore, the optimal timing of surgery and the effect of different surgical choices on the prognosis of patients with multiple ggns will be investigated.

Eligibility criteria:
inclusion criteria: 1. age greater than 18 years 2. have two or more ggns on ct imaging 3. diameter of ggns \> 5mm and ≤ 3cm 4. ggns must be greater than half ground glass exclusion criteria: 1. patients who have a history of lung cancer 2. patients who have undergone chemotherapy, radiotherapy or targeted therapy before surgery 3. pregnant women

Keywords: multiple pulmonary nodules lung neoplasms